Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis

Current Opinion in Neurology

Volumn 20, Issue 3, 2007, Pages 343-350

  Wingerchuk, Dean M ^a   Lucchinetti, Claudia F ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Acute disseminated encephalomyelitis; Immunopathology; Multiple sclerosis; Neuromyelitis optica; Pathogenesis

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; GELATINASE B; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DEMYELINATION; ENCEPHALOMYELITIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; MACROPHAGE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; REVIEW; SEX DIFFERENCE; SPINAL CORD; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

AQUAPORIN 4; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; DIAGNOSIS, DIFFERENTIAL; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PREDICTIVE VALUE OF TESTS;

EID: 34248354831     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3280be58d8     Document Type: Review

References (78)

1. Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin 2005; 23:17-38.
2. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald criteria'. Ann Neurol 2005; 58:840-846.
3. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004; 62:226-233.
4. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61:602-611.
5. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202:473-477.
6. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-2112.
7. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-1489. The authors used a quantitative approach to derive new diagnostic criteria for NMO. The criteria are 99% sensitive and 90% specific for distinguishing NMO from MS with an optic-spinal presentation.
8. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63:390-396. This paper describes the spectrum of brain MRI findings in NMO, emphasizing that brain lesions are compatible with the diagnosis and that up to 10% of cases will meet MS MRI criteria.
9. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63:964-968. A small number of patients with NMO have lesions involving the hypothalamic, thalamic, and periependymal regions which correlate with areas of known high aquaporin-4 density.
10. Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005; 62:1673-1680.
11. Dale RC, Branson JA. Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis? Arch Dis Child 2005; 90:636-639.
12. Wingerchuk DM. The clinical course of acute disseminated encephalomyelitis. Neurol Res 2006; 28:341-347.
13. Wingerchuk DM. Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues. Adv Neurol 2006; 98:303-318.
14. Leake JA, Albani S, Kao AS, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004; 23:756-764.
15. Mikaeloff Y, Suissa S, Vallee L, et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr 2004; 144:246-252.
16. Frohman EM, Racke MK, Raine CS. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006; 354:942-955. A timely update of the known pathogenesis of MS lesions and delineation of unanswered questions.
17. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717.
18. Ludwin SK. The pathogenesis of multiple sclerosis: relating human pathology to experimental studies. J Neuropathol Exp Neurol 2006; 65:305-318.
19. Pittock SJ, McClelland RL, Achenbach SJ, et al. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry 2005; 76:1693-1697.
20. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424-435.
21. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354:610-621. This wide-ranging summary provides an excellent account of chemokines research.
22. Hemmer B, Nessler S, Zhou D, et al. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006; 2:201-211.
23. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43:465-471.
24. Baranzini SE, Jeong MC, Butunoi C, et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999; 163:5133-5144.
25. Colombo M, Dono M, Gazzola P, et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000; 164:2782-2789.
26. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201:195-200.
27. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128(Pt 7):1667-1676.
28. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5:170-175.
29. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349:139-145.
30. Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006; 180 (1-2):50-62.
31. Wang KC, Koprivica V, Kim JA, et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002; 417:941-944.
32. John GR, Shankar SL, Shafit-Zagardo B, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002; 8:1115-1121.
33. Imitola J, Chitnis T, Khoury SJ. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol 2006; 63:25-33. The authors propose a model of how MS evolves into a progressive disorder.
34. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51:682-689.
35. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15-23.
36. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910. This landmark trial demonstrated that integrin inhibition could result in efficient control of brain MRI activity of MS and reduce clinical relapses and disability.
37. Rice GP, Hartung HP, Calabresi PA. Antialpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64:1336-1342.
38. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63:1779-1787.
39. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58:143-146.
40. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125(Pt 7):1450-1461.
41. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107-1114.
42. Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol 2006; 13:655-658. This paper contributes to the clinical association of NMO with other humoral autoimmune diseases.
43. Kister I, Gulati S, Boz C, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006; 63:851-856. This paper contributes to the clinical association of NMO with other humoral autoimmune diseases.
44. Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004; 63:2363-2370.
45. Ishizu T, OsoegawaM, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128 (Pt 5):988-1002.
46. Lefkowitz D, Angelo JN. Neuromyelitis optica with unusual vascular changes. Arch Neurol 1984; 41:1103-1105.
47. Agre P, Kozono D. Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett 2003; 555:72-78.
48. Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. Nat Rev Neurosci 2003; 4:991-1001.
49. Jarius S, Friedemann P, Aktas O, et al. Antibodies to aquaporin-4 in the diagnosis and differential diagnosis of neuromyelitis optica. In: Program and Abstracts of the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2006; Madrid, Spain.
50. Littleton ET, Jacob A, Boggild M, Palace J. An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica. Mult Scler 2006; 12:S156.
51. Marignier R, De Seze J, Durand-Dubief F, et al. NMO-IgG: a French experience. Mult Scler 2006; 12:S4.
52. Zuliani L, Blanco Y, Tavolato B, et al. Neuromyelitis optica autoantibody (NMO-IgG) in patients with suspected NMO or limited forms of NMO. Mult Scler 2006; 12:S155-S156.
53. Lennon VA. Changing concepts in CNS demyelinating disorders: autoimmune water channelopathies. In: Program and abstracts of the American Academy of Neurology 58th Annual Meeting; 1-8 April 2006; San Diego, California. Plenary session.
54. Misu T, Fujihara K, Nakamura M, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 2006; 209:269-275. This paper describes loss of aquaporin-4 in NMO lesions with relative sparing in MS lesions.
55. Roemer SF, Parisi JE, Lennon VA, et al. Pattern specific loss of aquaporin 4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (in press).
56. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006; 116:2385-2392. Describes the development of an NMO-like EAE model and the accompanying editorial nicely outlines the relevance of the model and comparisons with human NMO.
57. Ransohoff RM. A mighty mouse: building a better model of multiple sclerosis. J Clin Invest 2006; 116:2313-2316. Describes the development of an NMO-like EAE model and the accompanying editorial nicely outlines the relevance of the model and comparisons with human NMO.
58. Bettelli E, Baeten D, Jager A, et al. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006; 116:2393-2402. Describes the development of an NMO-like EAE model and the accompanying editorial nicely outlines the relevance of the model and comparisons with human NMO.
59. Lalive PH, Menge T, Barman I, et al. Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology 2006; 67:176-177. About 25% of patients with NMO are NMO-IgG seronegative. This paper describes use of microarrays to identify other potential candidate autoantibodies associated with NMO.
60. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 2006; 77:1073-1075. This paper confirmed both the association of NMO-IgG with severe optic-spinal demyelinating disease in Asians and the fact that brain MRI lesions do not preclude the diagnosis.
61. Weinshenker BG, Wingerchuk DM, Nakashima I, et al. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006; 5:110-111. A succinct account of the case-supporting identity of NMO and Asian optic-spinal MS.
62. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (in press).
63. Hart MN, Earle KM. Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975; 38:585-591.
64. Prineas JW, McDonald WI, Franklin RJM. Demyelinating diseases. 7th ed London: Arnold; 2002.
65. Oppenheimer DR. Demyelinating diseases. London: Edward Arnold; 1976.
66. van Bogaert L. Postinfectious encephalomyelitis and multiple sclerosis: the significance of perivenous encephalomyelitis. J Neuropathol Exp Neurol 1950; 9:219-249.
67. Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123 (Pt 12):2407-2422.
68. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129 (Pt 8):1953-1971. A comprehensive account of what has been gleaned from several decades of EAE research.
69. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005; 58:939-945.
70. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8:681-694.
71. Fuller KG, Olson JK, Howard LM, et al. Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods Mol Med 2004; 102:339-361.
72. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985; 230:1043-1045.
73. Hemachudha T, Griffin DE, Giffels JJ, et al. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. N Engl J Med 1987; 316:369-374.
74. Plesner AM, Arlien-Soborg P, Herning M. Neurological complications to vaccination against Japanese encephalitis. Eur J Neurol 1998; 5:479-485.
75. Franciotta D, Zardini E, Ravaglia S, et al. Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. J Neurol Sci 2006; 247:202-207.
76. Ishizu T, Minohara M, Ichiyama T, et al. CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis. J Neuroimmunol 2006; 175 (1-2): 52-58.
77. Ichiyama T, Kajimoto M, Suenaga N, et al. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. J Neuroimmunol 2006; 172 (1-2):182-186. The near future will see more studies like this: comparisons of new immunologic adrances amongst cases defined clinically as MS or ADEM.
78. Martino D, Branson JA, Church AJ, et al. Soluble adhesion molecules in acute disseminated encephalomyelitis. Pediatr Neurol 2005; 33:255-258.